Interview: Peter Van Der Velden, Managing General Partner, Lumira Capital,…
The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of…
Lumira Capital, Canada
Last updated: 13.02.2014
Built on a foundation that leverages over 20 years of North American venture capital experience, the Lumira Capital team has substantial experience helping to build transformational health and life science companies.
Our goal is to make investments in market leading companies and work in partnership with those companies to develop and implement strategies to build significant businesses that in turn allow us to generate profitable exits that maximize returns within a reasonable time frame.
As partners in our businesses we are committed to the success of our portfolio companies. We roll up our sleeves and work side by side with our entrepreneurs, their management teams and our syndication partners – leveraging our internal resources, knowledge networks, deep industry expertise and relationships, as well as our operational and leadership experience to help the businesses achieve their full potential.
141 Adelaide Street West, Suite 770,
Toronto, ON, CA. M5H 3L5
t.416.213.4223 f.416.213.4232
Interviews
Related
Canada / Federal Consultations on a National Strategy for Rare Disease Drugs
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
Canada / The Evolution of Medical Cannabis Legislation
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
Canada / Has the Time Truly Come for Trudeau’s ‘National Pharmacare’?
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
Canada / Pharma News Roundup September 2020
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
Pricing / Drugmakers Push Back Against Canada's New Regulations
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory…
Alzheimer's / Canadian-Led Innovation Post-Aducanumab
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for…
Canada / Global Pharma has Reinvented R&D: Will Canadian Start-Ups Lead the Next Phase?
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Opinion / A New Approach to Rare Diseases in Canada
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to…
Pharma Faces / Marina Vasiliou, Biogen Canada
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied…
Canada / Collective Impact in the Health Charity Sector
Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to…
Patents: A Key Factor in Winning the Cannabis Arms Race
A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial…
Comprehensive Access to Medicines should be the Priority for National Pharmacare…
Canada is the only developed country with a universal healthcare system that does not provide universal coverage of…
